

Grant Olear
Shapleigh
LD 104

As a medical cannabis patient, I strongly oppose the proposed regulations calling for excessive testing, needless track-and-trace requirements, and arbitrary potency limits across all cannabis products.

These changes would raise costs, reduce access, and put small, local producers at risk—hurting both patients and the local economy. We've already seen what happens when local manufacturing disappears: product quality drops, prices go up, and community trust erodes. Why are we doing the same to cannabis?

The current system works. It gives patients safe, affordable access to medicine made by people we know and trust. Overregulating it in ways that benefit large corporations undermines everything that makes our program successful. It would allow publicly-traded companies with a responsibility to shareholders over patients to gain a significant stronghold over what is currently looked at as one of the strongest medical markets in the country. Do not hurt Maine industry to benefit out-of-state, foreign investment corporations.

Please support sustainable, community-based cannabis by rejecting these harmful proposals.